Genomewide Screen for Synthetic Lethal Interactions with Mutant KRAS in Lung Cancer
Technical Report,01 Aug 2016,31 Jul 2017
University of Mississippi Medical Center Jackson United States
Pagination or Media Count:
Many factors are known to contribute to the development of lung cancer one of the important contributing ones is genetic mutations. For example, KRAS mutations account for 22 lung cancer cases. Thus, researchers have be entrying hard to develop drugs against mutant KRAS. However, to date no effective pharmacological inhibitors targeting mutant RAS have reached the clinic for various reasons. Therefore, the search is still going on. Synthetic lethal approach is a new concept that RAS mutant cancer cells rely on other genes or pathways to survive. Thus, these genes or pathways serve as potential targets for lung cancer therapy. Our proposed work uses the same concept but with a novel approach.
- Medicine and Medical Research